Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
27.28 PLN | +1.11% | +1.11% | -10.70% |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 719.5 | 95.21 | 57.49 | 98.24 | 94.25 | 122 |
Enterprise Value (EV) 1 | 755.3 | 95.29 | 86.65 | 121.4 | 111 | 105.1 |
P/E ratio | 28.2 x | 6.61 x | 13.4 x | -7.27 x | -0.48 x | -2.3 x |
Yield | 0.71% | - | - | - | - | - |
Capitalization / Revenue | 3.54 x | 0.48 x | 0.33 x | 0.88 x | 0.78 x | 1.95 x |
EV / Revenue | 3.71 x | 0.48 x | 0.5 x | 1.09 x | 0.92 x | 1.68 x |
EV / EBITDA | 14.1 x | 2.66 x | 7.82 x | -4.24 x | -7.65 x | 6.33 x |
EV / FCF | -16 x | 3.97 x | 19.5 x | 55.2 x | -10 x | -7.49 x |
FCF Yield | -6.26% | 25.2% | 5.12% | 1.81% | -9.97% | -13.4% |
Price to Book | 4.26 x | 0.5 x | 0.29 x | 0.47 x | 1.99 x | 1.52 x |
Nbr of stocks (in thousands) | 3,607 | 3,607 | 3,607 | 4,328 | 4,976 | 9,953 |
Reference price 2 | 199.5 | 26.40 | 15.94 | 22.70 | 18.94 | 12.26 |
Announcement Date | 3/21/18 | 3/26/19 | 4/29/20 | 4/1/21 | 4/28/22 | 4/27/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 203.4 | 199.4 | 173.9 | 111.7 | 120.6 | 62.72 |
EBITDA 1 | 53.57 | 35.85 | 11.08 | -28.61 | -14.51 | 16.6 |
EBIT 1 | 41.82 | 24.72 | -0.084 | -38.46 | -24.46 | 15.96 |
Operating Margin | 20.57% | 12.4% | -0.05% | -34.42% | -20.29% | 25.44% |
Earnings before Tax (EBT) 1 | 36.59 | 21.57 | -2.655 | -39.95 | -164.4 | 17.87 |
Net income 1 | 25.54 | 14.42 | 4.279 | -12.92 | -180.6 | -30.4 |
Net margin | 12.56% | 7.23% | 2.46% | -11.56% | -149.83% | -48.48% |
EPS 2 | 7.080 | 3.997 | 1.186 | -3.122 | -39.73 | -5.333 |
Free Cash Flow 1 | -47.3 | 23.99 | 4.433 | 2.199 | -11.07 | -14.04 |
FCF margin | -23.26% | 12.03% | 2.55% | 1.97% | -9.18% | -22.38% |
FCF Conversion (EBITDA) | - | 66.91% | 40.02% | - | - | - |
FCF Conversion (Net income) | - | 166.39% | 103.59% | - | - | - |
Dividend per Share 2 | 1.420 | - | - | - | - | - |
Announcement Date | 3/21/18 | 3/26/19 | 4/29/20 | 4/1/21 | 4/28/22 | 4/27/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 35.8 | 0.07 | 29.2 | 23.2 | 16.8 | - |
Net Cash position 1 | - | - | - | - | - | 16.9 |
Leverage (Debt/EBITDA) | 0.6682 x | 0.002064 x | 2.633 x | -0.8104 x | -1.155 x | - |
Free Cash Flow 1 | -47.3 | 24 | 4.43 | 2.2 | -11.1 | -14 |
ROE (net income / shareholders' equity) | 16.1% | 8.72% | -0.13% | -12.8% | -142% | 28.4% |
ROA (Net income/ Total Assets) | 7.93% | 5.11% | -0.02% | -8.48% | -7.69% | 8.94% |
Assets 1 | 322 | 282.4 | -24,451 | 152.3 | 2,350 | -340.1 |
Book Value Per Share 2 | 46.80 | 52.60 | 54.30 | 47.90 | 9.520 | 8.040 |
Cash Flow per Share 2 | 9.020 | 16.70 | 3.090 | 3.740 | 2.340 | 2.630 |
Capex 1 | 2.18 | 1.38 | 3.82 | 0.42 | 9.91 | - |
Capex / Sales | 1.07% | 0.69% | 2.2% | 0.37% | 8.22% | - |
Announcement Date | 3/21/18 | 3/26/19 | 4/29/20 | 4/1/21 | 4/28/22 | 4/27/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-10.70% | 66.27M | |
-14.41% | 18.54B | |
-46.16% | 2.65B | |
+17.00% | 1.85B | |
-0.51% | 1.66B | |
+26.25% | 1.23B | |
-13.90% | 989M | |
-21.76% | 896M | |
-19.12% | 673M | |
+5.66% | 490M |
- Stock Market
- Equities
- MDG Stock
- Financials Medicalgorithmics S.A.